ISAR-REACT 5 Trial – Review

ISAR-REACT 5 Trial – Review ISAR-REACT 5 Trial [1] was a multicenter study with randomized patients who presented which acute coronary syndrome for whom an invasive strategy was planned, to either ticagrelor or prasugrel. It was an open label trial. Primary end point was a composite of death, myocardial infarction or stroke at one year. A major secondary safety endpoint was bleeding. This was an investigator-initiated trial funded by German Center for Cardiovascular Research and Deutsches Herzzentrum München (German Heart Center Munich). 4,018 patients were randomized in the study. Primary composite endpoint occurred in 9.3% in ticagrelor group and 6.9% in the prasugrel group. Mortality was 4.5% in ticagrelor group and 3.7% in the prasugrel group. Definite stent thrombosis occurred in 1.1% in the ticagrelor group and 0.6% in the prasugrel group. Major bleeding occurred in 5.4% of patients in the ticagrelor group and 4.8% in prasugrel group (P=0.46). The authors of the study report concluded that in acute coronary syndrome with or without ST segment elevation, the composite end point of death, myocardial infarction or stroke was significantly lower among those who received prasugrel than those who received ticagrelor. Incidence of major bleeding was similar in the two groups. Both ticagrelor and prasugrel have been shown to be superior to clopidogrel in earlier randomized trials in acute coronary syndrome [2,3]. But prasugrel use was only in those scheduled for percuta...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs